Skip to content
DataLookout
Menu

NCT07579949

A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Mar 29, 2027 to Sep 30, 2027 Show 5 more changesShow less
    • Recruitment opened
    • Eligibility criteria expanded, about 31 words
    • Study completion pushed from Apr 29, 2027 to Dec 30, 2027
    • Start date changed from estimate of Jun 18, 2026 to Jun 16, 2026
    • Site details revised at 8 of 8 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety evaluation
Timeframe: From signing the informed consent to 4 weeks after the last dose

Arms and interventions

Cohort 1Experimental

Study Drug

Cohort 2Experimental

Study Drug

Cohort 3Placebo comparator

Placebo

Drugs: SNH-119014 dose 1, SNH-119014 dose 2, Placebo

Sites

8 sites in 1 country